Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Perioperative Therapy for GEJ Adenocarcinoma
NCT07493382Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of retlirafusp alfa in gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07493382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493382.